Singh AP - Search Results

1

Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.

Singh AP, Krzyzanski W, Martin SW, Weber G, Betts A, Ahmad A, Abraham A, Zutshi A, Lin J, Singh P. Singh AP, et al. Among authors: singh p. AAPS J. 2015 Mar;17(2):389-99. doi: 10.1208/s12248-014-9690-8. Epub 2014 Dec 3. AAPS J. 2015. PMID: 25445845 Free PMC article.

2

Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.

Singh AP, Shin YG, Shah DK. Singh AP, et al. Pharm Res. 2015 Nov;32(11):3508-25. doi: 10.1007/s11095-015-1626-1. Epub 2015 Feb 11. Pharm Res. 2015. PMID: 25666843 Review.

3

Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).

Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK. Singh AP, et al. AAPS J. 2016 Jul;18(4):861-75. doi: 10.1208/s12248-016-9904-3. Epub 2016 Mar 30. AAPS J. 2016. PMID: 27029797 Free PMC article.

4

Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).

Singh AP, Shah DK. Singh AP, et al. AAPS J. 2017 Jul;19(4):1054-1070. doi: 10.1208/s12248-017-0071-y. Epub 2017 Apr 3. AAPS J. 2017. PMID: 28374319 Free PMC article.

5

Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats.

Nguyen LM, Singh AP, Wiczling P, Krzyzanski W. Nguyen LM, et al. Among authors: singh ap. Front Pharmacol. 2018 Apr 10;9:316. doi: 10.3389/fphar.2018.00316. eCollection 2018. Front Pharmacol. 2018. PMID: 29692726 Free PMC article.

6

Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.

Singh AP, Guo L, Verma A, Wong GG, Thurber GM, Shah DK. Singh AP, et al. AAPS J. 2020 Jan 14;22(2):28. doi: 10.1208/s12248-019-0387-x. AAPS J. 2020. PMID: 31938899 Free PMC article.

7

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.

Singh AP, Sharma S, Shah DK. Singh AP, et al. J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):567-582. doi: 10.1007/s10928-016-9495-8. Epub 2016 Sep 26. J Pharmacokinet Pharmacodyn. 2016. PMID: 27670282 Free PMC article.

8

A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.

Singh AP, Shah DK. Singh AP, et al. J Pharm Sci. 2019 Jul;108(7):2465-2475. doi: 10.1016/j.xphs.2019.01.034. Epub 2019 Feb 18. J Pharm Sci. 2019. PMID: 30790581 Free PMC article.

9

Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect.

Singh AP, Seigel GM, Guo L, Verma A, Wong GG, Cheng HP, Shah DK. Singh AP, et al. J Pharmacol Exp Ther. 2020 Jul;374(1):184-199. doi: 10.1124/jpet.119.262287. Epub 2020 Apr 9. J Pharmacol Exp Ther. 2020. PMID: 32273304 Free PMC article.

10

Translational PK-PD model for in vivo CAR-T-cell therapy delivered using CAR mRNA-loaded polymeric nanoparticle vector.

Kim SJ, Mugundu GM, Singh AP. Kim SJ, et al. Among authors: singh ap. Clin Transl Sci. 2024 Dec;17(12):e70101. doi: 10.1111/cts.70101. Clin Transl Sci. 2024. PMID: 39696762 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,265 results

Search Page

Filters